Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 559

1.

HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target.

Fok JHL, Hedayat S, Zhang L, Aronson LI, Mirabella F, Pawlyn C, Bright MD, Wardell CP, Keats JJ, De Billy E, Rye CS, Chessum NEA, Jones K, Morgan GJ, Eccles SA, Workman P, Davies FE.

Clin Cancer Res. 2018 Feb 1. doi: 10.1158/1078-0432.CCR-17-1594. [Epub ahead of print]

PMID:
29391353
2.

Oncogenic RAC1 and NRAS drive resistance to endoplasmic reticulum stress through MEK/ERK signalling.

Bright MD, Clarke PA, Workman P, Davies FE.

Cell Signal. 2018 Jan 9;44:127-137. doi: 10.1016/j.cellsig.2018.01.004. [Epub ahead of print]

3.

Objective, Quantitative, Data-Driven Assessment of Chemical Probes.

Antolin AA, Tym JE, Komianou A, Collins I, Workman P, Al-Lazikani B.

Cell Chem Biol. 2018 Feb 15;25(2):194-205.e5. doi: 10.1016/j.chembiol.2017.11.004. Epub 2017 Dec 14.

4.

Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766).

Chessum NEA, Sharp SY, Caldwell JJ, Pasqua AE, Wilding B, Colombano G, Collins I, Ozer B, Richards M, Rowlands M, Stubbs M, Burke R, McAndrew PC, Clarke PA, Workman P, Cheeseman MD, Jones K.

J Med Chem. 2018 Feb 8;61(3):918-933. doi: 10.1021/acs.jmedchem.7b01406. Epub 2018 Jan 5.

5.

Structure-based drug design: aiming for a perfect fit.

van Montfort RLM, Workman P.

Essays Biochem. 2017 Nov 8;61(5):431-437. doi: 10.1042/EBC20170052. Print 2017 Nov 8. Review.

PMID:
29118091
6.

MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma.

Lampis A, Carotenuto P, Vlachogiannis G, Cascione L, Hedayat S, Burke R, Clarke P, Bosma E, Simbolo M, Scarpa A, Yu S, Cole R, Smyth E, Mateos JF, Begum R, Hezelova B, Eltahir Z, Wotherspoon A, Fotiadis N, Bali MA, Nepal C, Khan K, Stubbs M, Hahne JC, Gasparini P, Guzzardo V, Croce CM, Eccles S, Fassan M, Cunningham D, Andersen JB, Workman P, Valeri N, Braconi C.

Gastroenterology. 2017 Nov 4. pii: S0016-5085(17)36331-X. doi: 10.1053/j.gastro.2017.10.043. [Epub ahead of print]

7.

Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.

Whittaker SR, Barlow C, Martin MP, Mancusi C, Wagner S, Self A, Barrie E, Te Poele R, Sharp S, Brown N, Wilson S, Jackson W, Fischer PM, Clarke PA, Walton MI, McDonald E, Blagg J, Noble M, Garrett MD, Workman P.

Mol Oncol. 2017 Oct 24. doi: 10.1002/1878-0261.12148. [Epub ahead of print]

8.

The role of high expectations of self and social desirability in emotional processing in individuals with irritable bowel syndrome: A qualitative study.

Sibelli A, Chalder T, Everitt H, Workman P, Bishop FL, Moss-Morris R.

Br J Health Psychol. 2017 Nov;22(4):737-762. doi: 10.1111/bjhp.12264. Epub 2017 Sep 1.

PMID:
28862389
9.

RNAi screen reveals synthetic lethality between cyclin G-associated kinase and FBXW7 by inducing aberrant mitoses.

Dolly SO, Gurden MD, Drosopoulos K, Clarke P, de Bono J, Kaye S, Workman P, Linardopoulos S.

Br J Cancer. 2017 Sep 26;117(7):954-964. doi: 10.1038/bjc.2017.277. Epub 2017 Aug 22.

10.

Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology.

Blagg J, Workman P.

Cancer Cell. 2017 Aug 14;32(2):268-270. doi: 10.1016/j.ccell.2017.07.010. No abstract available.

11.

In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.

Al-Saffar NMS, Agliano A, Marshall LV, Jackson LE, Balarajah G, Sidhu J, Clarke PA, Jones C, Workman P, Pearson ADJ, Leach MO.

PLoS One. 2017 Jul 13;12(7):e0180263. doi: 10.1371/journal.pone.0180263. eCollection 2017.

12.

Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology.

Blagg J, Workman P.

Cancer Cell. 2017 Jul 10;32(1):9-25. doi: 10.1016/j.ccell.2017.06.005. Review. Erratum in: Cancer Cell. 2017 Aug 14;32(2):268-270.

13.

Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma.

Ang JE, Pal A, Asad YJ, Henley AT, Valenti M, Box G, de Haven Brandon A, Revell VL, Skene DJ, Venturi M, Rueger R, Meresse V, Eccles SA, de Bono JS, Kaye SB, Workman P, Banerji U, Raynaud FI.

Mol Cancer Ther. 2017 Oct;16(10):2315-2323. doi: 10.1158/1535-7163.MCT-16-0881. Epub 2017 Jun 21.

PMID:
28637716
14.

Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy.

Agliano A, Balarajah G, Ciobota DM, Sidhu J, Clarke PA, Jones C, Workman P, Leach MO, Al-Saffar NMS.

Oncotarget. 2017 Jul 18;8(29):47969-47983. doi: 10.18632/oncotarget.18206.

15.

SiGNet: A signaling network data simulator to enable signaling network inference.

Coker EA, Mitsopoulos C, Workman P, Al-Lazikani B.

PLoS One. 2017 May 17;12(5):e0177701. doi: 10.1371/journal.pone.0177701. eCollection 2017.

16.

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.

Pawlyn C, Bright MD, Buros AF, Stein CK, Walters Z, Aronson LI, Mirabella F, Jones JR, Kaiser MF, Walker BA, Jackson GH, Clarke PA, Bergsagel PL, Workman P, Chesi M, Morgan GJ, Davies FE.

Blood Cancer J. 2017 Mar 31;7(3):e549. doi: 10.1038/bcj.2017.27.

17.

How Much Longer Will We Put Up With $100,000 Cancer Drugs?

Workman P, Draetta GF, Schellens JHM, Bernards R.

Cell. 2017 Feb 9;168(4):579-583. doi: 10.1016/j.cell.2017.01.034.

18.

Inhibitors of cyclin-dependent kinases as cancer therapeutics.

Whittaker SR, Mallinger A, Workman P, Clarke PA.

Pharmacol Ther. 2017 May;173:83-105. doi: 10.1016/j.pharmthera.2017.02.008. Epub 2017 Feb 5. Review.

PMID:
28174091
19.

Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen.

Cheeseman MD, Chessum NE, Rye CS, Pasqua AE, Tucker MJ, Wilding B, Evans LE, Lepri S, Richards M, Sharp SY, Ali S, Rowlands M, O'Fee L, Miah A, Hayes A, Henley AT, Powers M, Te Poele R, De Billy E, Pellegrino L, Raynaud F, Burke R, van Montfort RL, Eccles SA, Workman P, Jones K.

J Med Chem. 2017 Jan 12;60(1):180-201. doi: 10.1021/acs.jmedchem.6b01055. Epub 2016 Dec 22.

PMID:
28004573
20.

Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases.

Clarke PA, Ortiz-Ruiz MJ, TePoele R, Adeniji-Popoola O, Box G, Court W, Czasch S, El Bawab S, Esdar C, Ewan K, Gowan S, De Haven Brandon A, Hewitt P, Hobbs SM, Kaufmann W, Mallinger A, Raynaud F, Roe T, Rohdich F, Schiemann K, Simon S, Schneider R, Valenti M, Weigt S, Blagg J, Blaukat A, Dale TC, Eccles SA, Hecht S, Urbahns K, Workman P, Wienke D.

Elife. 2016 Dec 9;5. pii: e20722. doi: 10.7554/eLife.20722.

21.

Imaging biomarker roadmap for cancer studies.

O'Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brady M, Brown G, Buckley DL, Chenevert TL, Clarke LP, Collette S, Cook GJ, deSouza NM, Dickson JC, Dive C, Evelhoch JL, Faivre-Finn C, Gallagher FA, Gilbert FJ, Gillies RJ, Goh V, Griffiths JR, Groves AM, Halligan S, Harris AL, Hawkes DJ, Hoekstra OS, Huang EP, Hutton BF, Jackson EF, Jayson GC, Jones A, Koh DM, Lacombe D, Lambin P, Lassau N, Leach MO, Lee TY, Leen EL, Lewis JS, Liu Y, Lythgoe MF, Manoharan P, Maxwell RJ, Miles KA, Morgan B, Morris S, Ng T, Padhani AR, Parker GJ, Partridge M, Pathak AP, Peet AC, Punwani S, Reynolds AR, Robinson SP, Shankar LK, Sharma RA, Soloviev D, Stroobants S, Sullivan DC, Taylor SA, Tofts PS, Tozer GM, van Herk M, Walker-Samuel S, Wason J, Williams KJ, Workman P, Yankeelov TE, Brindle KM, McShane LM, Jackson A, Waterton JC.

Nat Rev Clin Oncol. 2017 Mar;14(3):169-186. doi: 10.1038/nrclinonc.2016.162. Epub 2016 Oct 11. Review.

22.

A systematic review with meta-analysis of the role of anxiety and depression in irritable bowel syndrome onset.

Sibelli A, Chalder T, Everitt H, Workman P, Windgassen S, Moss-Morris R.

Psychol Med. 2016 Nov;46(15):3065-3080. Epub 2016 Sep 8. Review.

PMID:
27605134
23.

The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate-Lactate Exchange in BRAF-Mutant Human Melanoma Cells.

Delgado-Goni T, Miniotis MF, Wantuch S, Parkes HG, Marais R, Workman P, Leach MO, Beloueche-Babari M.

Mol Cancer Ther. 2016 Dec;15(12):2987-2999. Epub 2016 Oct 7.

24.

Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9.

Rye CS, Chessum NE, Lamont S, Pike KG, Faulder P, Demeritt J, Kemmitt P, Tucker J, Zani L, Cheeseman MD, Isaac R, Goodwin L, Boros J, Raynaud F, Hayes A, Henley AT, de Billy E, Lynch CJ, Sharp SY, Te Poele R, Fee LO, Foote KM, Green S, Workman P, Jones K.

Medchemcomm. 2016 Aug 1;7(8):1580-1586. Epub 2016 Jun 13.

25.

A fragment-based approach applied to a highly flexible target: Insights and challenges towards the inhibition of HSP70 isoforms.

Jones AM, Westwood IM, Osborne JD, Matthews TP, Cheeseman MD, Rowlands MG, Jeganathan F, Burke R, Lee D, Kadi N, Liu M, Richards M, McAndrew C, Yahya N, Dobson SE, Jones K, Workman P, Collins I, van Montfort RL.

Sci Rep. 2016 Oct 6;6:34701. doi: 10.1038/srep34701.

26.

Polypharmacology in Precision Oncology: Current Applications and Future Prospects.

Antolin AA, Workman P, Mestres J, Al-Lazikani B.

Curr Pharm Des. 2016;22(46):6935-6945. doi: 10.2174/1381612822666160923115828. Review.

27.

Critical parameters in targeted drug development: the pharmacological audit trail.

Banerji U, Workman P.

Semin Oncol. 2016 Aug;43(4):436-45. doi: 10.1053/j.seminoncol.2016.06.001. Epub 2016 Jun 14. Review.

28.

Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers.

Carotenuto P, Fassan M, Pandolfo R, Lampis A, Vicentini C, Cascione L, Paulus-Hock V, Boulter L, Guest R, Quagliata L, Hahne JC, Ridgway R, Jamieson T, Athineos D, Veronese A, Visone R, Murgia C, Ferrari G, Guzzardo V, Evans TRJ, MacLeod M, Feng GJ, Dale T, Negrini M, Forbes SJ, Terracciano L, Scarpa A, Patel T, Valeri N, Workman P, Sansom O, Braconi C.

Gut. 2017 Jul;66(7):1268-1277. doi: 10.1136/gutjnl-2016-312278. Epub 2016 Sep 12.

29.

Minimizing bias in target selection by exploiting multidisciplinary Big Data and the protein interactome.

Al-Lazikani B, Workman P.

Future Med Chem. 2016 Sep;8(14):1711-6. doi: 10.4155/fmc-2016-0133. Epub 2016 Sep 1. No abstract available.

30.

Drug discovery in advanced prostate cancer: translating biology into therapy.

Yap TA, Smith AD, Ferraldeschi R, Al-Lazikani B, Workman P, de Bono JS.

Nat Rev Drug Discov. 2016 Oct;15(10):699-718. doi: 10.1038/nrd.2016.120. Epub 2016 Jul 22. Review.

PMID:
27444228
31.

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors.

Vaughan L, Clarke PA, Barker K, Chanthery Y, Gustafson CW, Tucker E, Renshaw J, Raynaud F, Li X, Burke R, Jamin Y, Robinson SP, Pearson A, Maira M, Weiss WA, Workman P, Chesler L.

Oncotarget. 2016 Sep 6;7(36):57525-57544. doi: 10.18632/oncotarget.10544.

32.

2,8-Disubstituted-1,6-Naphthyridines and 4,6-Disubstituted-Isoquinolines with Potent, Selective Affinity for CDK8/19.

Mallinger A, Schiemann K, Rink C, Sejberg J, Honey MA, Czodrowski P, Stubbs M, Poeschke O, Busch M, Schneider R, Schwarz D, Musil D, Burke R, Urbahns K, Workman P, Wienke D, Clarke PA, Raynaud FI, Eccles SA, Esdar C, Rohdich F, Blagg J.

ACS Med Chem Lett. 2016 Mar 28;7(6):573-8. doi: 10.1021/acsmedchemlett.6b00022. eCollection 2016 Jun 9.

33.

Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.

Ferraldeschi R, Welti J, Powers MV, Yuan W, Smyth T, Seed G, Riisnaes R, Hedayat S, Wang H, Crespo M, Nava Rodrigues D, Figueiredo I, Miranda S, Carreira S, Lyons JF, Sharp S, Plymate SR, Attard G, Wallis N, Workman P, de Bono JS.

Cancer Res. 2016 May 1;76(9):2731-42. doi: 10.1158/0008-5472.CAN-15-2186.

34.

Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development.

Yap TA, Banerji U, de Bono JS, Workman P.

J Clin Oncol. 2016 Jul 10;34(20):2431-2. doi: 10.1200/JCO.2016.67.0075. Epub 2016 May 2. No abstract available.

PMID:
27138581
35.

Exploiting Protein Conformational Change to Optimize Adenosine-Derived Inhibitors of HSP70.

Cheeseman MD, Westwood IM, Barbeau O, Rowlands M, Dobson S, Jones AM, Jeganathan F, Burke R, Kadi N, Workman P, Collins I, van Montfort RL, Jones K.

J Med Chem. 2016 May 26;59(10):4625-36. doi: 10.1021/acs.jmedchem.5b02001. Epub 2016 May 11.

36.

Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.

Ang JE, Pandher R, Ang JC, Asad YJ, Henley AT, Valenti M, Box G, de Haven Brandon A, Baird RD, Friedman L, Derynck M, Vanhaesebroeck B, Eccles SA, Kaye SB, Workman P, de Bono JS, Raynaud FI.

Mol Cancer Ther. 2016 Jun;15(6):1412-24. doi: 10.1158/1535-7163.MCT-15-0815. Epub 2016 Apr 5.

37.

Fused imidazoles as potential chemical scaffolds for inhibition of heat shock protein 70 and induction of apoptosis. Synthesis and biological evaluation of phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthrolines.

Patel A, Sharp SY, Hall K, Lewis W, Stevens MF, Workman P, Moody CJ.

Org Biomol Chem. 2016 Apr 28;14(16):3889-905. doi: 10.1039/c6ob00471g. Epub 2016 Apr 1.

PMID:
27035072
38.

Blocking the survival of the nastiest by HSP90 inhibition.

Workman P, Clarke PA, Al-Lazikani B.

Oncotarget. 2016 Jan 26;7(4):3658-61. doi: 10.18632/oncotarget.6971.

39.

Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.

Mallinger A, Schiemann K, Rink C, Stieber F, Calderini M, Crumpler S, Stubbs M, Adeniji-Popoola O, Poeschke O, Busch M, Czodrowski P, Musil D, Schwarz D, Ortiz-Ruiz MJ, Schneider R, Thai C, Valenti M, de Haven Brandon A, Burke R, Workman P, Dale T, Wienke D, Clarke PA, Esdar C, Raynaud FI, Eccles SA, Rohdich F, Blagg J.

J Med Chem. 2016 Feb 11;59(3):1078-101. doi: 10.1021/acs.jmedchem.5b01685. Epub 2016 Jan 21.

40.

Distinctive Behaviors of Druggable Proteins in Cellular Networks.

Mitsopoulos C, Schierz AC, Workman P, Al-Lazikani B.

PLoS Comput Biol. 2015 Dec 23;11(12):e1004597. doi: 10.1371/journal.pcbi.1004597. eCollection 2015 Dec.

41.

A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.

Dale T, Clarke PA, Esdar C, Waalboer D, Adeniji-Popoola O, Ortiz-Ruiz MJ, Mallinger A, Samant RS, Czodrowski P, Musil D, Schwarz D, Schneider K, Stubbs M, Ewan K, Fraser E, TePoele R, Court W, Box G, Valenti M, de Haven Brandon A, Gowan S, Rohdich F, Raynaud F, Schneider R, Poeschke O, Blaukat A, Workman P, Schiemann K, Eccles SA, Wienke D, Blagg J.

Nat Chem Biol. 2015 Dec;11(12):973-980. doi: 10.1038/nchembio.1952. Epub 2015 Oct 26.

42.

Corrigendum: The promise and peril of chemical probes.

Arrowsmith CH, Audia JE, Austin C, Baell J, Bennett J, Blagg J, Bountra C, Brennan PE, Brown PJ, Bunnage ME, Buser-Doepner C, Campbell RM, Carter AJ, Cohen P, Copeland RA, Cravatt B, Dahlin JL, Dhanak D, Edwards AM, Frederiksen M, Frye SV, Gray N, Grimshaw CE, Hepworth D, Howe T, Huber KV, Jin J, Knapp S, Kotz JD, Kruger RG, Lowe D, Mader MM, Marsden B, Mueller-Fahrnow A, Müller S, O'Hagan RC, Overington JP, Owen DR, Rosenberg SH, Ross R, Roth B, Schapira M, Schreiber SL, Shoichet B, Sundström M, Superti-Furga G, Taunton J, Toledo-Sherman L, Walpole C, Walters MA, Willson TM, Workman P, Young RN, Zuercher WJ.

Nat Chem Biol. 2015 Nov;11(11):887. doi: 10.1038/nchembio1115-887c. No abstract available.

PMID:
26485080
43.

Maximizing the Therapeutic Potential of HSP90 Inhibitors.

Butler LM, Ferraldeschi R, Armstrong HK, Centenera MM, Workman P.

Mol Cancer Res. 2015 Nov;13(11):1445-51. doi: 10.1158/1541-7786.MCR-15-0234. Epub 2015 Jul 28. Review.

44.

Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.

Gurden MD, Westwood IM, Faisal A, Naud S, Cheung KM, McAndrew C, Wood A, Schmitt J, Boxall K, Mak G, Workman P, Burke R, Hoelder S, Blagg J, Van Montfort RL, Linardopoulos S.

Cancer Res. 2015 Aug 15;75(16):3340-54. doi: 10.1158/0008-5472.CAN-14-3272. Epub 2015 Jul 22.

45.

The promise and peril of chemical probes.

Arrowsmith CH, Audia JE, Austin C, Baell J, Bennett J, Blagg J, Bountra C, Brennan PE, Brown PJ, Bunnage ME, Buser-Doepner C, Campbell RM, Carter AJ, Cohen P, Copeland RA, Cravatt B, Dahlin JL, Dhanak D, Edwards AM, Frederiksen M, Frye SV, Gray N, Grimshaw CE, Hepworth D, Howe T, Huber KV, Jin J, Knapp S, Kotz JD, Kruger RG, Lowe D, Mader MM, Marsden B, Mueller-Fahrnow A, Müller S, O'Hagan RC, Overington JP, Owen DR, Rosenberg SH, Roth B, Ross R, Schapira M, Schreiber SL, Shoichet B, Sundström M, Superti-Furga G, Taunton J, Toledo-Sherman L, Walpole C, Walters MA, Willson TM, Workman P, Young RN, Zuercher WJ.

Nat Chem Biol. 2015 Aug;11(8):536-41. doi: 10.1038/nchembio.1867. No abstract available. Erratum in: Nat Chem Biol. 2015 Nov;11(11):887. Nat Chem Biol. 2015 Aug;11(8):541. Roth, Brian [Corrected to Roth, Bryan] and Frederiksen, Mathias [Added].

46.

Drugging PI3K in cancer: refining targets and therapeutic strategies.

Yap TA, Bjerke L, Clarke PA, Workman P.

Curr Opin Pharmacol. 2015 Aug;23:98-107. doi: 10.1016/j.coph.2015.05.016. Epub 2015 Jun 25. Review.

47.

Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.

Mallinger A, Crumpler S, Pichowicz M, Waalboer D, Stubbs M, Adeniji-Popoola O, Wood B, Smith E, Thai C, Henley AT, Georgi K, Court W, Hobbs S, Box G, Ortiz-Ruiz MJ, Valenti M, De Haven Brandon A, TePoele R, Leuthner B, Workman P, Aherne W, Poeschke O, Dale T, Wienke D, Esdar C, Rohdich F, Raynaud F, Clarke PA, Eccles SA, Stieber F, Schiemann K, Blagg J.

J Med Chem. 2015 Feb 26;58(4):1717-35. doi: 10.1021/jm501436m. Epub 2015 Feb 13.

48.

Services provided by community pharmacies in Wayne County, Michigan: a comparison by ZIP code characteristics.

Erickson SR, Workman P.

J Am Pharm Assoc (2003). 2014 Nov-Dec;54(6):618-24. doi: 10.1331/JAPhA.2014.14105.

PMID:
25379982
49.

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.

Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, Clarke PA, Raynaud FI, Levy G, Ware JA, Mazina K, Lin R, Wu J, Fredrickson J, Spoerke JM, Lackner MR, Yan Y, Friedman LS, Kaye SB, Derynck MK, Workman P, de Bono JS.

Clin Cancer Res. 2015 Jan 1;21(1):77-86. doi: 10.1158/1078-0432.CCR-14-0947. Epub 2014 Nov 4.

50.

Chemical biology approaches to target validation in cancer.

Blagg J, Workman P.

Curr Opin Pharmacol. 2014 Aug;17:87-100. doi: 10.1016/j.coph.2014.07.007. Epub 2014 Aug 28. Review.

PMID:
25175311

Supplemental Content

Loading ...
Support Center